Co-Diagnostics Regains Compliance with Nasdaq Listing Requirements - PR Newswire
π Co-Diagnostics (CODX) has officially regained compliance with all Nasdaq listing criteria.
π° The specific $1.00 bid price rule requirement has been satisfied and the listing matter is closed.
π Trading of Co-Diagnostics shares on the Nasdaq Capital Market resumes effective March 11, 2026.
π Management states that compliance enhances capital flexibility and shareholder confidence.
𧬠The company continues to focus on clinical performance studies for its PCR point-of-care platform.
β οΈ The Co-Dx PCR platform remains under FDA review and is not yet available for sale.
Bullish Signals
- Co-Diagnostics has successfully resolved its Nasdaq listing compliance issues, specifically the bid price rule.
- The closure of the listing matter removes immediate delisting risk and restores normal trading status.
- Regaining compliance provides enhanced flexibility in capital markets operations.
- Shareholders have received renewed confidence regarding the company's standing on the exchange.
Full Analysis
Co-Diagnostics, Inc. (NASDAQ: CODX) announced on March 10, 2026, that it has regained compliance with all Nasdaq listing requirements, specifically resolving the $1.00 bid price rule issue. The company received formal confirmation from Nasdaq Stock Market LLC on March 9, 2026, marking the closure of the previously disclosed listing matter.
As a direct result of regaining compliance, Co-Diagnostics shares will resume trading on the Nasdaq Capital Market effective March 11, 2026. Management views this milestone as an enhancement to capital markets flexibility and a source of renewed confidence for shareholders following the resolution of the delisting risk.